{
  "first_published_at": "2010-09-13", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON093855", 
  "title": "Isotretinoin: risk of serious skin reactions", 
  "tags": "{\"parsed_therapeutic\": [\"dermatology\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Dermatology\"]}", 
  "_document_number": 186, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "dermatology"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Isotretinoin: risk of serious skin reactions</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: September 2010</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported in association with isotretinoin, and may result in hospitalisation, disability, life-threatening events, or death. Patients starting isotretinoin treatment should be informed of the signs and symptoms of these serious skin eruptions and advised to stop treatment and contact their healthcare professional immediately if any of these arise<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Isotretinoin (brand leader Roaccutane) is a treatment for severe acne that is resistant to adequate courses of standard antibacterial or topical therapy. Over the past 25 years in which isotretinoin has been on the market, it has been prescribed worldwide for approximately 16 million patients.</p><h2>Association with serious skin reactions</h2><p>The licence holder for Roaccutane identified a possible association between isotretinoin use and serious skin conditions including erythema multiforme (EM), Stevens Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) after a thorough review of the data held in their global safety database. This review identified 66 cases of severe skin reactions have been reported worldwide to date in association with isotretinoin as follows: 15 cases of SJS; 44 cases of EM (in four of which rash symptoms reoccurred when isotretinoin was reintroduced); and five cases of TEN.</p><p>Although there are other possible explanations for most of the reports, a causal association between isotretinoin and these severe skin reactions cannot be excluded.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Serious skin reactions (EM, SJS, and TEN) have been reported in association with isotretinoin, which may result in hospitalisation, disability, life-threatening events, or death</li>\r\n\t\t\t\t<li>Isotretinoin must be immediately discontinued and appropriate supportive care given if symptoms of EM, SJS, or TEN develop</li>\r\n\t\t\t\t<li>Patients starting isotretinoin treatment should be informed of the signs and symptoms of these serious skin eruptions and advised to stop treatment and contact their healthcare professional immediately if any of these arise</li>\r\n\t\t\t</ul></div><p><strong>Further information</strong></p><p>See also <a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/07/WC500095336.pdf\" target=\"_blank\" title=\"report from the European Pharmacovigilance Working Party, July 2010\">report from the European Pharmacovigilance Working Party, July 2010</a></p><p>&nbsp;</p><p><em>Article citation: Drug Safety Update Sept 2010, vol 4 issue 2: A2.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Isotretinoin (brand leader Roaccutane) is a treatment for severe acne that is resistant to adequate courses of standard antibacterial or topical therapy. Over the past 25 years in which isotretinoin has been on the market, it has been prescribed worldwide for approximately 16 million patients.</p><h2>Association with serious skin reactions</h2><p>The licence holder for Roaccutane identified a possible association between isotretinoin use and serious skin conditions including erythema multiforme (EM), Stevens Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) after a thorough review of the data held in their global safety database. This review identified 66 cases of severe skin reactions have been reported worldwide to date in association with isotretinoin as follows: 15 cases of SJS; 44 cases of EM (in four of which rash symptoms reoccurred when isotretinoin was reintroduced); and five cases of TEN.</p><p>Although there are other possible explanations for most of the reports, a causal association between isotretinoin and these severe skin reactions cannot be excluded.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Serious skin reactions (EM, SJS, and TEN) have been reported in association with isotretinoin, which may result in hospitalisation, disability, life-threatening events, or death</li>\r\n\t\t\t\t<li>Isotretinoin must be immediately discontinued and appropriate supportive care given if symptoms of EM, SJS, or TEN develop</li>\r\n\t\t\t\t<li>Patients starting isotretinoin treatment should be informed of the signs and symptoms of these serious skin eruptions and advised to stop treatment and contact their healthcare professional immediately if any of these arise</li>\r\n\t\t\t</ul></div><p><strong>Further information</strong></p><p>See also <a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/07/WC500095336.pdf\" target=\"_blank\" title=\"report from the European Pharmacovigilance Working Party, July 2010\">report from the European Pharmacovigilance Working Party, July 2010</a></p><p>&#160;</p><p><em>Article citation: Drug Safety Update Sept 2010, vol 4 issue 2: A2.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2010-09-01", 
  "date_last_modified": "2010-10-05", 
  "_assets": [], 
  "_item_id": 186, 
  "summary": "Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported in association with isotretinoin, and may result in hospitalisation, disability, life-threatening events, or death. Patients starting isotretinoin treatment should be informed of the signs and symptoms of these serious skin eruptions and advised to stop treatment and contact their healthcare professional immediately if any of these arise", 
  "body": "Article date: September 2010\n\nIsotretinoin (brand leader Roaccutane) is a treatment for severe acne that is resistant to adequate courses of standard antibacterial or topical therapy. Over the past 25 years in which isotretinoin has been on the market, it has been prescribed worldwide for approximately 16 million patients.\n\n## Association with serious skin reactions\n\nThe licence holder for Roaccutane identified a possible association between isotretinoin use and serious skin conditions including erythema multiforme (EM), Stevens Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) after a thorough review of the data held in their global safety database. This review identified 66 cases of severe skin reactions have been reported worldwide to date in association with isotretinoin as follows: 15 cases of SJS; 44 cases of EM (in four of which rash symptoms reoccurred when isotretinoin was reintroduced); and five cases of TEN.\n\nAlthough there are other possible explanations for most of the reports, a causal association between isotretinoin and these severe skin reactions cannot be excluded.\n\nAdvice for healthcare professionals:  \n  \n  * Serious skin reactions (EM, SJS, and TEN) have been reported in association with isotretinoin, which may result in hospitalisation, disability, life-threatening events, or death  \n  * Isotretinoin must be immediately discontinued and appropriate supportive care given if symptoms of EM, SJS, or TEN develop  \n  * Patients starting isotretinoin treatment should be informed of the signs and symptoms of these serious skin eruptions and advised to stop treatment and contact their healthcare professional immediately if any of these arise  \n  \nFurther information\n\nSee also [report from the European Pharmacovigilance Working Party, July 2010](http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/07/WC500095336.pdf)\n\nÂ \n\nArticle citation: Drug Safety Update Sept 2010, vol 4 issue 2: A2.\n"
}